From: Impurity profiling method development and validation of metformin hydrochloride and teneligliptin hydrobromide hydrate in their combination tablet dosage form by using RP-HPLC with UV/PDA detector
Time in min
% mobile phase A
% mobile phase B
0.1
75
25
10.0
70
30
45.0
40
60
55.0
55.01
65.0